Year: 2008
Type: review
Abstract: rimary biliary cirrhosis (PBC) is a chronic cholestatic liver disease that affects up to one in 700 women in western populations (female to male ratio is approximately 10 to 1, with the disease typically presenting over the age of 40 years). 1 2 PBC is characterised histologically by damage to, and eventual loss of, the biliary epithelial cells (BEC) lining small intrahepatic bile ducts.BEC loss is typically accompanied by a significant portal tract inflammatory infiltrate that is mixed in phenotype (T cells (CD4 and CD8, with the latter predominating in the periductal areas), B cells, macrophages, eosinophils and natural killer cells).3 4 Early descriptions of PBC emphasised the predominant role played by the progression of bile duct loss, accompanied by increasing portal tract and linking fibrosis leading to biliary cirrhosis, in the clinical expression of PBC, and described an aggressive and uniformly fatal condition.5 Increased awareness of the condition and, in particular, the availability of diagnostic tools such as serology has led to broader and earlier diagnosis.6 This has had the effect that we now recognise PBC far more frequently than was previously the case, and typically do so at an earlier stage in the disease process.Broadening of the diagnostic base has, in addition, led us to appreciate that there is a significant subgroup within the PBC population who have a low risk of disease progression and who are unlikely to develop end-stage liver disease during a normal lifetime (but who remain at risk of developing the often life-altering symptoms of the disease such as fatigue, which are seemingly unrelated to the severity of the underlying liver disease).2 7 8 The factors that determine individual risk of disease progression remain unclear, precluding us, at present, from targeting disease-modifying therapies at ''high-risk'' patients.Study of the pathogenesis of PBC has focused, until relatively recently, almost entirely on immunological aspects of the disease.9 PBC was one of the first conditions in which the presence of autoantibodies in the serum was identified, and was one of the first conditions in which the antigen specificity of this autoreactive response was characterised. 3 This led, quite naturally, to the view that PBC is an autoimmune disease.This led, again not unreasonably (but largely unsuccessfully), to a focus on developing and applying therapies aimed at modifying this increasingly well-characterised autoreactive immune response.More recently, however, the true complexities of the processes seemingly contributing to PBC pathogenesis have begun to be appreciated and the exclusively autoimmune disease model has been challenged. PATHOLOGICAL FACTORS IN PBC cPBC pathogenesis from an immune system perspective PBC is characterised immunologically by the breakdown of immune self-tolerance to highly conserved mitochondrial and nuclear antigens (table 1). 3 10-19 The first autoreactive responses to be characterised in PBC were the serum antibody responses directed at antigens present on the inner mitochondrial membrane (antimitochondrial antibodies; AMA).AMA, which are present, often at very high titre, in over 95% of patients, are directed at the members of the 2-oxoacid dehydroganese complex family of multi-enzyme complexes.These complexes, which all play important roles in mitochondrial energetics, share a common multicomponent, multidomain structure.The dominant autoantibody response in PBC is directed at pyruvate dehydrogenase complex (PDC), although reactivity is seen to a lesser extent to all other 2-oxoacid dehydroganese complex family members (table 1).Within PDC, reactivity is seen, in particular, to the dihydrolipoamide acetyltransferase (E2) and enzyme 3 binding protein (E3BP) components.Reactivity is seen to these two antigens alone in over 90% of PBC patients.It was appreciated from relatively early on that the antibodies reactive with these two enzymes are fully crossreactive and that they can block the function of both enzymes.The mechanistic explanation for these two, in retrospect key, observations is the reactivity seen to a highly conserved structural motif present within both PDC-E2 and E3BP, 11 which consists of the binding domain for a lipoic acid (LA) co-factor that plays an essential role in enzyme function.The
Source: Postgraduate Medical Journal
Author: D E J Jones
Institution: Newcastle University
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: primary biliary cirrhosis, pathogenesis, cholestasis, autoantibodies, autoimmune hypothesis, disease progression, fibrosis, portal inflammation, T cells, B cells, macrophages, natural killer cells, disease-modifying therapy, early diagnosis, end-stage liver disease, sex differences, age of onset, genetic susceptibility, environmental factors
Open Access status: bronze
Funder: Medical Research Council
OpenAlex ID: W2114006962
